These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 25519801)

  • 21. Frequency of recurrence among MDR-tB cases 'successfully' treated with standardised short-course chemotherapy.
    Migliori GB; Espinal M; Danilova ID; Punga VV; Grzemska M; Raviglione MC
    Int J Tuberc Lung Dis; 2002 Oct; 6(10):858-64. PubMed ID: 12365571
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of the effectiveness of 2 treatment regimens in patients with isoniazid-resistant tuberculosis.
    Tabarsi P; Baghaei P; Hemmati N; Mirsaeidi M; Kazempour M; Mansouri D; Masjedi MR
    East Mediterr Health J; 2009; 15(6):1346-50. PubMed ID: 20218123
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tuberculosis drug resistance and treatment outcomes under DOTS settings in large cities in the Philippines.
    Ohkado A; Aguiman L; Adlawan S; Baring E; Quirante O; Suchi M; Endo S; Fujiki A; Mori T
    Int J Tuberc Lung Dis; 2006 Mar; 10(3):283-9. PubMed ID: 16562708
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment outcomes of drug-resistant tuberculosis in the Netherlands, 2005-2015.
    Pradipta IS; Van't Boveneind-Vrubleuskaya N; Akkerman OW; Alffenaar JC; Hak E
    Antimicrob Resist Infect Control; 2019; 8():115. PubMed ID: 31338162
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment outcomes of rifampin-sparing treatment in patients with pulmonary tuberculosis with rifampin-mono-resistance or rifampin adverse events: A retrospective cohort analysis.
    Park S; Jo KW; Lee SD; Kim WS; Shim TS
    Respir Med; 2017 Oct; 131():43-48. PubMed ID: 28947041
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Age, nutritional status and INH acetylator status affect pharmacokinetics of anti-tuberculosis drugs in children.
    Ramachandran G; Hemanth Kumar AK; Bhavani PK; Poorana Gangadevi N; Sekar L; Vijayasekaran D; Banu Rekha VV; Ramesh Kumar S; Ravichandran N; Mathevan G; Swaminathan S
    Int J Tuberc Lung Dis; 2013 Jun; 17(6):800-6. PubMed ID: 23676165
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Results of a 12-month regimen for drug-resistant pulmonary tuberculosis.
    Pérez-Guzmán C; Vargas MH; Martínez-Rossier LA; Torres-Cruz A; Villarreal-Velarde H
    Int J Tuberc Lung Dis; 2002 Dec; 6(12):1102-9. PubMed ID: 12546119
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Isoniazid- and rifampin-resistant tuberculosis in San Diego County, California, United States, 1993-2002.
    LoBue PA; Moser KS
    Int J Tuberc Lung Dis; 2005 May; 9(5):501-6. PubMed ID: 15875920
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predictors and mortality associated with treatment default in pulmonary tuberculosis.
    Kliiman K; Altraja A
    Int J Tuberc Lung Dis; 2010 Apr; 14(4):454-63. PubMed ID: 20202304
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early bactericidal activity of ethambutol, pyrazinamide and the fixed combination of isoniazid, rifampicin and pyrazinamide (Rifater) in patients with pulmonary tuberculosis.
    Botha FJ; Sirgel FA; Parkin DP; van de Wal BW; Donald PR; Mitchison DA
    S Afr Med J; 1996 Feb; 86(2):155-8. PubMed ID: 8619142
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Non conversion of sputum smears in new smear positive pulmonary tuberculosis patients in Yaoundé, Cameroon.
    Kuaban C; Bame R; Mouangue L; Djella S; Yomgni C
    East Afr Med J; 2009 May; 86(5):219-25. PubMed ID: 20084990
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influence of anti-tuberculosis drug resistance on the treatment outcome of pulmonary tuberculosis patients receiving DOTS in Riyadh, Saudi Arabia.
    Singla R; Al-Sharif N; Al-Sayegh MO; Osman MM; Shaikh MA
    Int J Tuberc Lung Dis; 2002 Jul; 6(7):585-91. PubMed ID: 12102297
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drug-resistant tuberculosis in Israel: risk factors and treatment outcomes.
    Mor Z; Goldblatt D; Kaidar-Shwartz H; Cedar N; Rorman E; Chemtob D
    Int J Tuberc Lung Dis; 2014 Oct; 18(10):1195-201. PubMed ID: 25216833
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Standardized controlled antitubercular therapy and results in 755 patients].
    Wiesner B; Cramer G; Hamel U; Roth G
    Z Erkr Atmungsorgane; 1991; 177(1-2):71-5. PubMed ID: 1808855
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Converging risk factors but no association between HIV infection and multidrug-resistant tuberculosis in Kazakhstan.
    van den Hof S; Tursynbayeva A; Abildaev T; Adenov M; Pak S; Bekembayeva G; Ismailov S
    Int J Tuberc Lung Dis; 2013 Apr; 17(4):526-31. PubMed ID: 23485387
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Radiometric vs. agar proportion methods for assessing ethionamide resistance and its clinical effects in multidrug-resistant tuberculosis.
    Cimen NO; Arslan Z; Saygi A; Ocak K; Babacan F; Kurutepe M
    Int J Tuberc Lung Dis; 2009 Jul; 13(7):907-13. PubMed ID: 19555543
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomised Phase II trial to evaluate the toxicity of high-dose rifampicin to treat pulmonary tuberculosis.
    Jindani A; Borgulya G; de Patiño IW; Gonzales T; de Fernandes RA; Shrestha B; Atwine D; Bonnet M; Burgos M; Dubash F; Patel N; Checkley AM; Harrison TS; Mitchison D;
    Int J Tuberc Lung Dis; 2016 Jun; 20(6):832-8. PubMed ID: 27155189
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rifampicin mono-resistant Mycobacterium tuberculosis in Bujumbura, Burundi: results of a drug resistance survey.
    Sanders M; Van Deun A; Ntakirutimana D; Masabo JP; Rukundo J; Rigouts L; Fissette K; Portaelst F
    Int J Tuberc Lung Dis; 2006 Feb; 10(2):178-83. PubMed ID: 16499257
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multidrug-resistant tuberculosis at Srinagarind Hospital, Khon Kaen, Thailand.
    Reechaipichitkul W
    Southeast Asian J Trop Med Public Health; 2002 Sep; 33(3):570-4. PubMed ID: 12693593
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Results of a therapeutic trial comparing a 6-month regimen to a 12-month regimen in the treatment of pulmonary tuberculosis in the Algerian Sahara. Final report: results 3 years after the onset of treatment].
    Berkani M; Chaulet P; Darbyshire JH; Nunn A; Fox W
    Rev Mal Respir; 1986; 3(2):73-85. PubMed ID: 3726263
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.